4.8 Article

Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia

Journal

CANCER CELL
Volume 23, Issue 2, Pages 200-214

Publisher

CELL PRESS
DOI: 10.1016/j.ccr.2013.01.011

Keywords

-

Funding

  1. Cole Foundation
  2. University Clinic of Essen
  3. Max-Eder fellowship from the German Cancer fund
  4. University of Cincinnati Cancer Therapeutics T32 training grant [T32-CA117846]
  5. Leukaemia and Lymphoma Research UK
  6. CancerFree Kids
  7. Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  8. Leukemia and Lymphoma Society of America
  9. NIH [CA105152, CA159845]
  10. Center of Excellence in Molecular Hematology [DK090971]
  11. Canada Research Chair (Tier 1)
  12. Canadian Institutes of Health Research (CIHR) [MOP-84238, MOP-111011]
  13. BBSRC [BB/I00050X/1] Funding Source: UKRI
  14. Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish
  15. Cancer Research UK [12765] Funding Source: researchfish
  16. Medical Research Council [MC_PC_12009] Funding Source: researchfish
  17. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [G0900729/1] Funding Source: researchfish

Ask authors/readers for more resources

Most patients with acute lymphoblastic leukemia (ALL) fail current treatments highlighting the need for better therapies. Because oncogenic signaling activates a p53-dependent DNA damage response and apoptosis, leukemic cells must devise appropriate countermeasures. We show here that growth factor independence 1 (Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses and lowers the threshold for p53-induced cell death. Specifically, Gfi1 restricts p53 activity and expression of proapoptotic p53 targets such as Box, Noxa (Pmaip1), and Puma (Bbc3). Subsequently, Gfi1 ablation cures mice from leukemia and limits the expansion of primary human T-ALL xenografts in mice. This suggests that targeting Gfi1 could improve the prognosis of patients with T-ALL or other lymphoid leukemias.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available